That is what I guessed and some longs here also predicted what you just described. That proves they are not complacent and really using their time wisely while waiting for TLD and publication.
Thanks for sharing this Nick. They are not just saying it but they are working on several things in parallel.
Why aren’t they communicating non TLD/Journal publication matters. Why are we having to guess on status of countless topics. This is getting out of control
I am pretty sure that was part of a press release in the spring…that they would begin testing Flaskworks in summer 2021. Nothing public since then tho.
Nick119, if they were already testing Flaskworks on their own, they already knew the results by now. They already knew if the Dendritic Cells harvested are of same quality or better or less quality with Flaskworks. I would also think potential buyers would not issue buy out offer without knowing Flaskworks can achieve at least same results critical to pave the way to Flaskwork's certification imo.
Who do you think is testing Flaskworks on their own? How? And where?
It doesn’t require duplication, or make sense to me. Advent has been contracted to test the system, and when it has been sufficiently tested, to perform the equivalency study and develop the new automated process. They have the knowledge, skill, and facility.
Instead, what makes more sense to me is that the technical team from Flaskworks has been working to develop the MicroDEN device into a commercial manufacturing system. MicroDEN was designed for clinical use, potentially to lower the cost for clinical trials, but it’s not ideal for commercial production. Shashi Murthy understood this and described a number of features in the patents that would likely be necessary for commercial production. From the patent:
So the commercial system may have multiple culture chambers and pumps running in parallel to be able to culture multiple treatments (10-12?) at the same time, and have multiple sensors to be able to monitor and control the culture process in real time. And this system will have be integrated with the Autolomous, AutoloMATE software that Advent will be using at Sawston, which digitizes workflows, maintains electronic batch manufacturing records, and tracks the batch throughout the manufacturing process, as well as Autolomous’ CLOCK scheduling software that coordinates the entire supply chain; hospitals for patient leukapheresis and dosing, logistics transporters, and the manufacturing equipment.
And what further makes me think at least some development work has been achieved, is that I kinda doubt that Michael Bigger would say the following about the former MicroDEN system:
Michael Bigger @biggercapital Oct 8 In awe with FLASKWORKS potential.
Oct 10 Thought Experiment: Clean Room Disruption? FLASKWORKS. Solid Tumors Disruption? DC-VAX. Inoperable Solid tumors disruption? DC-VAX Direct ,,, and then some. Is someone in the room playing a very long game?